Oral semaglutide: real drug or TikTok hype?

What did @susacharmd actually say?

The creator presented oral semaglutide (Rybelsus) as "the oral Ozempic, if you will," confirmed it contains the same active ingredient as Ozempic and Wegovy, and told viewers to start at "3 milligram dose" before bumping to 7.5 milligrams the following month. She also said side effects are "way more treatable than all of the diseases that come along with obesity." That last line is doing a lot of work, and it deserves scrutiny.

The framing is mostly accurate at the surface level. Oral semaglutide is FDA-approved under the brand name Rybelsus, and yes, it shares an active ingredient with injectable semaglutide. But calling it "oral Ozempic" without more context is a simplification that could genuinely mislead patients comparing options.

Does the science back this up?

Partially. The dosing she described matches the FDA-approved Rybelsus titration schedule for type 2 diabetes, but Rybelsus is not FDA-approved for weight loss. That is a significant omission in a video categorized under weight management.

The PIONEER trial program (Aroda et al., 2019, The Lancet Diabetes and Endocrinology) established oral semaglutide's efficacy for glycemic control, not primarily for weight loss. The weight loss data for oral semaglutide at higher doses (25 mg, 50 mg) comes from the OASIS 1 trial (Knop et al., 2023, The Lancet), which tested doses not currently FDA-approved. The 3 mg and 7.5 mg doses she mentions produce meaningfully less weight loss than injectable Wegovy at 2.4 mg weekly. Bioavailability is roughly 1 percent for oral semaglutide versus near-complete absorption for the injectable. These are not equivalent formulations in clinical practice.

What did they get wrong (or right)?

She got the active ingredient right. Semaglutide is semaglutide, whether injected or swallowed. She correctly warned viewers not to "try to find the equivalent dose," which is genuinely good advice given the pharmacokinetic differences.

Where she went wrong: the claim that side effects are "way more treatable" than obesity-related diseases is an opinion dressed as a clinical fact. It is also incomplete. Oral semaglutide has a narrow administration window (taken 30 minutes before food with no more than 4 oz of water) that reduces tolerability for many patients. Davies et al. (2021, Diabetes Care) found gastrointestinal discontinuation rates were not trivial. Saying "great medications" exist to manage side effects is vague reassurance, not clinical guidance. Nausea management protocols exist, but they are not universally effective and do not apply to all patients equally.

Also worth noting: this video does not distinguish between Rybelsus (FDA-approved, brand-name oral semaglutide) and any compounded oral semaglutide products, which are a separate regulatory category with no established bioequivalence data.

What should you actually know?

Oral semaglutide at the doses discussed here is approved for type 2 diabetes management, not weight loss. If you are considering it specifically for weight, that is an off-label use at these doses. The higher-dose formulations showing more significant weight loss (OASIS 1 trial) are not yet FDA-approved for any indication.

The daily dosing requirement and strict food-timing rules make oral semaglutide less forgiving than weekly injectables for real-world adherence. A missed window is not just inconvenient, it can meaningfully reduce drug absorption. Aroda et al. (2019) noted that even minor deviations from administration instructions dropped bioavailability substantially.

Finally, the creator's framing of side effects as a minor detour on a "weight loss journey" undersells real discontinuation rates. Anyone weighing this option should have a direct conversation with a licensed provider, not a TikTok video, about their specific risk profile.

The bottom line

This is a doctor giving a mostly accurate but incomplete overview of oral semaglutide. The active ingredient claim is correct. The dosing numbers match the approved diabetes titration. But the weight loss framing, the side effect minimization, and the failure to distinguish between approved and unapproved uses make this video more promotional than educational. Useful starting point, poor substitute for a clinical consultation.